Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
puma pharmaceuticals stock price Off 54% - canerofset.com
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Puma Biotechnology
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Pharma (@PumaPharma) / Twitter
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
